| Log in

Ranbaxy Ends JV With Nihon Chemiphar

08 December, 2009

Ranbaxy Laboratories, which was bought out by Japanese major Daiichi Sankyo in 2008, has announced the termination of its joint venture with Nihon Chemiphar, a Tokyo based mid-sized pharma company.

Ranbaxy has sold its 50% stake in the joint venture company, Nippon Pharmaceutical Industry & Company Ltd, to Nihon Chemiphar. The Japanese firm has reportedly paid $18 million to Ranbaxy for its stake. Following the deal, Nippon Pharmaceutical becomes a wholly-owned subsidiary of Nihon Chemiphar.

Ranbaxy said, in a statement, “It was amicably concluded that it would be in the best interest of both companies to continue their generic businesses independently.” Ranbaxy will continue to supply generic products to Nihon Chemiphar in the transition period. Japan is the second largest pharma market in the world.


Leave Your Comment
Sun Pharma to acquire 14 Novartis brands in Japan for $293M

Sun Pharma to acquire 14 Novartis brands in Japan for $293M

Joseph Rai 2 years ago
Sun Pharmaceutical Industries Ltd will acquire 14 prescription brands from Swiss...
Zydus Cadila exiting business in Japan

Zydus Cadila exiting business in Japan

Lohit Jagwani 4 years ago
Gujarat-based drug maker Cadila Healthcare Ltd, which runs under the brand Zydus...
News Roundup: Tata- Sasken JV Called Off

News Roundup: Tata- Sasken JV Called Off

TEAM VCC 9 years ago
Lazard Asset LLC and Swiss Finance Sell Satyam Shares in Bulk Deals –...
No Comments

Ranbaxy Ends JV With Nihon Chemiphar

Powered by WordPress.com VIP